If you own PTI shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
Or please contact:
WeissLaw is investigating whether PTI’s board satisfied its fiduciary duties to its shareholders by conducting a fair and diligent process, agreeing to an equity split that provides fair value to PTI shareholders, and whether all information regarding the process leading to the proposed transaction and valuation of the deal will be fully and fairly disclosed to PTI shareholders. These issues are of particular concern in light of the fact that existing PTI shareholders will only retain a 32.5% ownership of the combined company.
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-proteostasis-therapeutics-inc-301118300.html